ReviewBreast care (Basel, Switzerland)2015
Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence.
Review in Breast care (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk Factors Related to Acute Radiation Dermatitis in Breast Cancer Patients After Radiotherapy: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer patients: efficacy and safety in a large, multi-institutional series.Journal of cancer research and clinical oncology · 2019Trial
- Phase II trial of hypofractionated VMAT-based treatment for early stage breast cancer: 2-year toxicity and clinical results.Radiation oncology (London, England) · 2016Trial
- Auto-segmentation of surgical clips for target volume delineation in post-lumpectomy breast cancer radiotherapy.BMC medical imaging · 2025Article
- Survival trends of patients with metaplastic breast carcinoma with different hormone receptor statuses: a SEER-based retrospective cohort study.BMC women's health · 2024Article
- Review
- Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer.Clinical and translational radiation oncology · 2023Article
- Article
- Article
- Hypofractionation and Concomitant Boost in Ductal Carcinoma In Situ (DCIS): Analysis of a Prospective Case Series with Long-Term Follow-Up.Life (Basel, Switzerland) · 2022Article
- Impact of CBCT frequency on target coverage and dose to the organs at risk in adjuvant breast cancer radiotherapy.Scientific reports · 2021Article
- Hypofractionated breast irradiation: a multidisciplinary review of the Senonetwork study group.Medical oncology (Northwood, London, England) · 2021Review
- Post-lumpectomy radiation therapy boost in breast cancer patients: evidence revisited.Ecancermedicalscience · 2021Review
- Omission of postoperative radiation after breast conserving surgery: A progressive paradigm shift towards precision medicine.Clinical and translational radiation oncology · 2020Review
- Intensity-Modulated Radiotherapy with Concomitant Boost After Breast Conserving Surgery: A Phase I-II Trial.Breast cancer (Dove Medical Press) · 2020Article
- Do hypofraction and large breast size reciprocally fit in breast cancer radiotherapy?Annals of translational medicine · 2019Article
- Simulation modeling for clinical trials evaluating radiotherapy omission in low-risk early breast cancer.Annals of translational medicine · 2018Article
- De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients.Medical oncology (Northwood, London, England) · 2018Review
- Volumetric modulated arc therapy (VMAT) to deliver nodal irradiation in breast cancer patients.Medical oncology (Northwood, London, England) · 2017Observational
- Ten-year results of accelerated hypofractionated adjuvant whole-breast radiation with concomitant boost to the lumpectomy cavity after conserving surgery for early breast cancer.Medical oncology (Northwood, London, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation therapy delivered with hypofractionation, which involves the delivery of a higher dose per fraction in fewer fractions (generally with a lower total nominal dose) over a shorter overall treatment time, is an established therapeutic option at least for a selected group of early breast cancer patients after breast-conserving surgery. Optimal delivery of the tumor bed boost dose in terms of timing, fractionation, and total dose whenever a hypofractionated schedule is employed has yet to be established. We herein present a review of the current evidence on the role of boost integration in whole breast radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.